The study aims to formulate solid lipid nanoparticles (SLNP's) of the poorly bioavailable drug α-Mangostin by central composite design and evaluate in-vitro drug characteristics. The contribution of ingredients on the Physico-chemical characteristics of formulated SLNP was investigated and further utilized for optimization of final formulation. For the formulation of SLNP’s, hot melt homogenisation method was used followed by ultrasonication approach. The solid lipids were Stearic acid and Precirol ATO5; the surfactant was Poloxamer 407, and the co-surfactant was Sodium taurocholate (STC) to provide the negative charge. The mean particle size, entrapment efficiency, zeta potential, and drug content percentage of the optimised formulation were 173.6 nm, 72.42 percent, -43.3 mV, and 20.46 percent, respectively. Amorphous form is confirmed with XRD. SEM analysis shown spherical morphology and particle size range between 145 to 218 nm. DSC and FTIR studies confirmed absence of drug-excipient interactions. The optimum surfactant and lipid combination produced high-quality solid lipid nanoparticles with stable release qualities for at least six months at room and refrigerator temperatures, according to the findings. SLNP’s may be used as an oral drug delivery carrier for α-Mangostin, according to the findings of this study, because of their exceptional properties.
Key words: Central composite design; Solid lipid nanoparticles; Alpha-mangostin; Hot melt homogenization, Ultrasonication.
|
